Week 144 Resistance Analyses of the Phase 3 EVG/COBI/FTC/TDF Studies

R Kulkarni*, ME Abram, MS Rhee, MW Fordyce, J Szwarcbarg, MD Miller, and KL White

Foster City, CA 94404

Opportunistic Infections
March 3-4, 2014
Boston, Massachusetts

Gilead Sciences, Inc., Foster City, CA, USA

Methods (cont’d)

• First Failure Resistance Analyses:
  - EVG/COBI/FTC/TDF (n=352)4 and EVG/COBI/FTC/TDF
  - EFV/FTC/TDF (n=352)

• The rate of resistance development to EVG/COBI/FTC/TDF
  - Linkage of integrase resistance mutations and M184V/I also
  - Compliance with the first failure samples for the EVG/COBI/FTC/TDF subjects with

Results (cont’d)

Table 2. Emergent Drug Resistance in Subjects with Viral Failure

![Image of Table 2]

Table 3. Genotypic and Phenotypic Analysis of the EVG/COBI/FTC/TDF Strategy Failures with Emergent Resistance Through Week 144

![Image of Table 3]

Conclusions

• High and durable efficacy was observed in subjects treated with
  - EVG/COBI/FTC/TDF
  - EVG/COBI/FTC/TDF and RAL
  - EVG/COBI/FTC/TDF and RAL in failing subjects

References & Acknowledgments

© 2014 Gilead Sciences, Inc. All rights reserved.